Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.40
WAT's Cash to Debt is ranked higher than
72% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. WAT: 1.40 )
WAT' s 10-Year Cash to Debt Range
Min: 0   Max: 198.95
Current: 1.4

0
198.95
Equity to Asset 0.49
WAT's Equity to Asset is ranked higher than
62% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. WAT: 0.49 )
WAT' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.66
Current: 0.49

0.13
0.66
F-Score: 4
Z-Score: 4.65
M-Score: -2.40
WACC vs ROIC
6.33%
34.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.03
WAT's Operating margin (%) is ranked higher than
96% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.34 vs. WAT: 26.03 )
WAT' s 10-Year Operating margin (%) Range
Min: 8.08   Max: 28.55
Current: 26.03

8.08
28.55
Net-margin (%) 21.70
WAT's Net-margin (%) is ranked higher than
96% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. WAT: 21.70 )
WAT' s 10-Year Net-margin (%) Range
Min: -1.78   Max: 25.03
Current: 21.7

-1.78
25.03
ROE (%) 23.55
WAT's ROE (%) is ranked higher than
95% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. WAT: 23.55 )
WAT' s 10-Year ROE (%) Range
Min: -12.26   Max: 68.79
Current: 23.55

-12.26
68.79
ROA (%) 11.61
WAT's ROA (%) is ranked higher than
93% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. WAT: 11.61 )
WAT' s 10-Year ROA (%) Range
Min: -1.81   Max: 22.73
Current: 11.61

-1.81
22.73
ROC (Joel Greenblatt) (%) 70.64
WAT's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.59 vs. WAT: 70.64 )
WAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 27.6   Max: 137.37
Current: 70.64

27.6
137.37
Revenue Growth (3Y)(%) 5.20
WAT's Revenue Growth (3Y)(%) is ranked higher than
79% of the 257 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. WAT: 5.20 )
WAT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.2   Max: 19.5
Current: 5.2

5.2
19.5
EBITDA Growth (3Y)(%) -1.40
WAT's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. WAT: -1.40 )
WAT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -1.4   Max: 69.7
Current: -1.4

-1.4
69.7
EPS Growth (3Y)(%) 2.60
WAT's EPS Growth (3Y)(%) is ranked higher than
77% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. WAT: 2.60 )
WAT' s 10-Year EPS Growth (3Y)(%) Range
Min: 2.6   Max: 79.2
Current: 2.6

2.6
79.2
» WAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

WAT Guru Trades in Q4 2013

Steven Cohen 12,666 sh (New)
Jim Simons 86,100 sh (New)
Paul Tudor Jones 8,545 sh (New)
Joel Greenblatt 13,049 sh (+222.52%)
Pioneer Investments 41,057 sh (unchged)
Chuck Royce 13,250 sh (unchged)
Andreas Halvorsen Sold Out
PRIMECAP Management 688,950 sh (-0.89%)
Ruane Cunniff 2,084,496 sh (-1.53%)
John Hussman 135,000 sh (-2.17%)
Jeremy Grantham 54,333 sh (-4.17%)
» More
Q1 2014

WAT Guru Trades in Q1 2014

Jeremy Grantham 134,409 sh (+147.38%)
PRIMECAP Management 1,040,561 sh (+51.04%)
Jim Simons 121,017 sh (+40.55%)
Steven Cohen 16,907 sh (+33.48%)
Chuck Royce 13,250 sh (unchged)
Joel Greenblatt Sold Out
Ruane Cunniff 2,074,156 sh (-0.5%)
John Hussman 115,000 sh (-14.81%)
Pioneer Investments 21,592 sh (-47.41%)
Paul Tudor Jones 4,300 sh (-49.68%)
» More
Q2 2014

WAT Guru Trades in Q2 2014

Jeremy Grantham 176,039 sh (+30.97%)
Paul Tudor Jones 4,400 sh (+2.33%)
Pioneer Investments 21,592 sh (unchged)
Chuck Royce 13,250 sh (unchged)
John Hussman Sold Out
Ruane Cunniff 2,066,476 sh (-0.37%)
PRIMECAP Management 1,035,761 sh (-0.46%)
Jim Simons 18,800 sh (-84.46%)
» More
Q3 2014

WAT Guru Trades in Q3 2014

Ray Dalio 3,600 sh (New)
Joel Greenblatt 137,466 sh (New)
Jim Simons 289,500 sh (+1439.89%)
Paul Tudor Jones 5,568 sh (+26.55%)
Chuck Royce 13,250 sh (unchged)
Pioneer Investments 21,592 sh (unchged)
Ruane Cunniff 2,050,578 sh (-0.77%)
Jeremy Grantham 174,539 sh (-0.85%)
PRIMECAP Management 983,434 sh (-5.05%)
» More
» Details

Insider Trades

Latest Guru Trades with WAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy0.14%$99.25 - $107.16 $ 119.0515%137466
Ray Dalio 2014-09-30 New Buy$99.25 - $107.16 $ 119.0515%3600
John Hussman 2014-06-30 Sold Out 0.93%$98.54 - $114.29 $ 119.0513%0
John Hussman 2014-03-31 Reduce -14.81%0.14%$98.04 - $114.94 $ 119.0510%115000
PRIMECAP Management 2014-03-31 Add 51.04%0.04%$98.04 - $114.94 $ 119.0510%1040561
Joel Greenblatt 2014-03-31 Sold Out 0.03%$98.04 - $114.94 $ 119.0510%0
Andreas Halvorsen 2013-12-31 Sold Out 0.57%$95.25 - $106.48 $ 119.0518%0
Joel Greenblatt 2013-12-31 Add 222.52%0.02%$95.25 - $106.48 $ 119.0518%13049
John Hussman 2013-09-30 New Buy0.81%$98.16 - $107.73 $ 119.0516%138000
Andreas Halvorsen 2013-09-30 New Buy0.57%$98.16 - $107.73 $ 119.0516%974002
Joel Greenblatt 2013-09-30 Reduce -35.98%0.01%$98.16 - $107.73 $ 119.0516%4046
Joel Greenblatt 2013-03-31 Add 46.55%0.01%$86.22 - $94.96 $ 119.0529%6740
Joel Greenblatt 2012-12-31 Reduce -33.14%0.01%$78.89 - $89.33 $ 119.0542%4599
John Hussman 2012-09-30 Sold Out 1.1%$74.66 - $85.24 $ 119.0550%0
Joel Greenblatt 2012-09-30 New Buy0.04%$74.66 - $85.24 $ 119.0550%6879
Ruane Cunniff 2012-06-30 Add 35.43%0.37%$76.65 - $94.19 $ 119.0543%2119159
PRIMECAP Management 2012-03-31 Reduce -47.3%0.11%$73.71 - $94.03 $ 119.0546%1060740
Ray Dalio 2012-03-31 Sold Out 0.03%$73.71 - $94.03 $ 119.0546%0
Joel Greenblatt 2012-03-31 Sold Out 0.03%$73.71 - $94.03 $ 119.0546%0
Ruane Cunniff 2011-12-31 Add 72.52%0.42%$71.61 - $83.14 $ 119.0555%1563999
Joel Greenblatt 2011-12-31 New Buy0.03%$71.61 - $83.14 $ 119.0555%2973
Ray Dalio 2011-12-31 New Buy0.03%$71.61 - $83.14 $ 119.0555%22873
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.40
WAT's P/E(ttm) is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.50 vs. WAT: 23.40 )
WAT' s 10-Year P/E(ttm) Range
Min: 9.62   Max: 32.47
Current: 23.4

9.62
32.47
Forward P/E 17.15
WAT's Forward P/E is ranked higher than
91% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.15 vs. WAT: 17.15 )
N/A
PE(NRI) 23.40
WAT's PE(NRI) is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.00 vs. WAT: 23.40 )
WAT' s 10-Year PE(NRI) Range
Min: 9.61   Max: 32.45
Current: 23.4

9.61
32.45
P/B 5.23
WAT's P/B is ranked higher than
63% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.69 vs. WAT: 5.23 )
WAT' s 10-Year P/B Range
Min: 4.38   Max: 20.15
Current: 5.23

4.38
20.15
P/S 5.07
WAT's P/S is ranked higher than
61% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. WAT: 5.07 )
WAT' s 10-Year P/S Range
Min: 2.05   Max: 5.87
Current: 5.07

2.05
5.87
PFCF 36.52
WAT's PFCF is ranked higher than
88% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 58.63 vs. WAT: 36.52 )
WAT' s 10-Year PFCF Range
Min: 9.67   Max: 42.67
Current: 36.52

9.67
42.67
POCF 28.97
WAT's POCF is ranked higher than
79% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.09 vs. WAT: 28.97 )
WAT' s 10-Year POCF Range
Min: 7.83   Max: 34.13
Current: 28.97

7.83
34.13
EV-to-EBIT 18.00
WAT's EV-to-EBIT is ranked higher than
88% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.90 vs. WAT: 18.00 )
WAT' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 25.2
Current: 18

8.4
25.2
PEG 7.09
WAT's PEG is ranked higher than
93% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. WAT: 7.09 )
WAT' s 10-Year PEG Range
Min: 0.6   Max: 9.06
Current: 7.09

0.6
9.06
Shiller P/E 25.01
WAT's Shiller P/E is ranked higher than
91% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 154.03 vs. WAT: 25.01 )
WAT' s 10-Year Shiller P/E Range
Min: 13.51   Max: 44.59
Current: 25.01

13.51
44.59
Current Ratio 4.88
WAT's Current Ratio is ranked higher than
85% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.73 vs. WAT: 4.88 )
WAT' s 10-Year Current Ratio Range
Min: 1.25   Max: 5.24
Current: 4.88

1.25
5.24
Quick Ratio 4.46
WAT's Quick Ratio is ranked higher than
88% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. WAT: 4.46 )
WAT' s 10-Year Quick Ratio Range
Min: 0.74   Max: 4.75
Current: 4.46

0.74
4.75
Days Inventory 114.84
WAT's Days Inventory is ranked higher than
72% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 118.39 vs. WAT: 114.84 )
WAT' s 10-Year Days Inventory Range
Min: 96.3   Max: 155.02
Current: 114.84

96.3
155.02
Days Sales Outstanding 79.56
WAT's Days Sales Outstanding is ranked higher than
68% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 68.35 vs. WAT: 79.56 )
WAT' s 10-Year Days Sales Outstanding Range
Min: 67.61   Max: 89.8
Current: 79.56

67.61
89.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 138.43
WAT's Price/Net Cash is ranked higher than
86% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. WAT: 138.43 )
WAT' s 10-Year Price/Net Cash Range
Min: 132.29   Max: 132.29
Current: 138.43

Price/Net Current Asset Value 19.08
WAT's Price/Net Current Asset Value is ranked higher than
83% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. WAT: 19.08 )
WAT' s 10-Year Price/Net Current Asset Value Range
Min: 18.23   Max: 2783.33
Current: 19.08

18.23
2783.33
Price/Tangible Book 5.23
WAT's Price/Tangible Book is ranked higher than
68% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.25 vs. WAT: 5.23 )
WAT' s 10-Year Price/Tangible Book Range
Min: 5   Max: 46.24
Current: 5.23

5
46.24
Price/DCF (Projected) 1.70
WAT's Price/DCF (Projected) is ranked higher than
86% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. WAT: 1.70 )
WAT' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 11.02
Current: 1.7

0.89
11.02
Price/Median PS Value 1.16
WAT's Price/Median PS Value is ranked higher than
74% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. WAT: 1.16 )
WAT' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 3.29
Current: 1.16

0.14
3.29
Price/Peter Lynch Fair Value 4.10
WAT's Price/Peter Lynch Fair Value is ranked higher than
91% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. WAT: 4.10 )
WAT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.68   Max: 3.92
Current: 4.1

0.68
3.92
Price/Graham Number 2.31
WAT's Price/Graham Number is ranked higher than
84% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.08 vs. WAT: 2.31 )
WAT' s 10-Year Price/Graham Number Range
Min: 2.21   Max: 10.76
Current: 2.31

2.21
10.76
Earnings Yield (Greenblatt) 5.60
WAT's Earnings Yield (Greenblatt) is ranked higher than
87% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. WAT: 5.60 )
WAT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4   Max: 11.9
Current: 5.6

4
11.9
Forward Rate of Return (Yacktman) 9.07
WAT's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. WAT: 9.07 )
WAT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6   Max: 27.6
Current: 9.07

6
27.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:WAZ.Germany,
Waters Corp incorporated as a Delaware corporation in 1991, is an analytical instrument manufacturer, mainly designs, manufactures, sells and services, through its Waters Division, high performance liquid chromatography, ultra performance liquid chromatography and mass spectrometry instrument systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. Waters became a publicly-traded company with its initial public offering ("IPO") in November 1995. The Company's two operating segments, Waters Division and TA Division, have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution and regulatory environments. The Waters Division's products and services primarily consist of high performance liquid chromatography ("HPLC"), ultra performance liquid chromatography ("UPLC" and together with HPLC, referred to as "LC"), mass spectrometry ("MS") and chemistry consumable products and related services. TA products and services primarily consist of thermal analysis, rheometry and calorimetry instrument systems and service sales. The Company's products are used by pharmaceutical, life science, biochemical, industrial, nutritional safety, environmental, academic and governmental customers. These customers use the Company's products to detect, identify, monitor and measure the chemical, physical and biological composition of materials and to predict the suitability of fine chemicals, pharmaceuticals, water, polymers and viscous liquids in various industrial, consumer goods and healthcare products. The Company's competitors include: Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc. In the markets served by the TA Division, the Company's principal competitors include: PerkinElmer, Inc., Mettler-Toledo International Inc., NETZSCH-Geraetebau GmbH, Thermo Fisher Scientific Inc., Malvern Instruments Ltd., Anton-Paar and General Electric Company. The Company is subject to federal, state and local laws, regulations and ordinances that govern activities or operations that may have adverse environmental effects, such as discharges to air and water as well as handling and disposal practices for solid and hazardous wastes and impose liability for the costs of cleaning up and certain damages resulting from sites of past spills, disposals or other releases of hazardous substances.
» More Articles for WAT

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MAS Dec 14 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
Our Investment Strategy and Portfolio Selection Nov 09 2014 
Guru-Held Stocks Trading At Historical Low P/B Oct 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B May 12 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 05 2014 


More From Other Websites
Waters Corp. (WAT) Stock Gained Today After Cantor Fitzgerald Increased Price Target Jan 28 2015
Joint Open Laboratory Established In China by Waters & the Chinese Pharmacopeia Commission Jan 28 2015
Waters (WAT) Earnings Report: Q4 2014 Conference Call Transcript Jan 27 2015
Waters Transforms Glycan Analysis with New UPLC and UPLC-MS Analytical Workflows Jan 27 2015
Waters Beats on Q4 Estimates on Surging Pharma Demand - Analyst Blog Jan 27 2015
Waters beats Street 4Q forecasts Jan 26 2015
Waters beats Street 4Q forecasts Jan 26 2015
Waters Corp Earnings Call scheduled for 5:00 pm ET today Jan 26 2015
Waters tops Street 4Q forecasts Jan 26 2015
Waters tops Street 4Q forecasts Jan 26 2015
Waters Reports Fourth Quarter 2014 Financial Results Jan 26 2015
WATERS CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 26 2015
Waters Reports Fourth Quarter 2014 Financial Results Jan 26 2015
Waters Corporation Q4 2014 Financial Results Webcast Invitation – Now January 26, 2015 at 5:00 PM... Jan 26 2015
Waters Corporation Q4 2014 Financial Results Webcast Invitation – Now January 26, 2015 at 5:00 PM... Jan 26 2015
Will Waters (WAT) Surprise Q4 Earnings on Innovations? - Analyst Blog Jan 23 2015
The Waters ionKey/MS Technology Named a Top Innovation for 2014 Jan 15 2015
The Waters ionKey/MS Technology Named a Top Innovation for 2014 Jan 15 2015
Friday's Market Recap Jan 09 2015
Waters Corporation Presentation at the 33rd Annual J.P. Morgan Healthcare Conference to Be Webcast... Jan 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK